Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.3K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

539
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
539
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

708
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
708
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.6K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.6K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

499
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
499
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

590
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
590

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulation of HIV-2 Vpx/Vpr expression by the poly-proline motif: Enhancement of protein dimerization and translation.

Virology·2026
Same author

Green Approach to Enhance Dissolution of Gliclazide: Thermoresponsive Solid Dispersion Based on Poloxamer 188/Propylene Glycol/Labrasol Ternary System.

Pharmaceutics·2026
Same author

Pharmacology of estrogen-related receptors (ERRs) agonists.

RSC chemical biology·2026
Same author

Impacts of storage conditions on the dissolution performance of commercial metronidazole tablets available in Saudi Arabia.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society·2026
Same author

Simplified synthesis of anti-oxidant small molecule <sup>OH</sup>PyN<sub>3</sub>.

MethodsX·2026
Same author

Massularosides E-N, triterpenoid saponins from the stem bark of Massularia acuminata, featuring rare N-acetylglucosamine and sulphoquinovose units.

Phytochemistry·2026

Related Experiment Video

Updated: Nov 11, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.8K

First In Class (S,E)-11-[2-(Arylmethylene)Hydrazono]-PBD Analogs As Selective CB2 Modulators Targeting

David Mingle1, Meirambek Ospanov2, Mohamed O Radwan3,4,5

  • 1Department of Chemistry, East Tennessee State University, Johnson City, TN 37614, USA.

Medicinal Chemistry Research : an International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents
|March 29, 2021
PubMed
Summary
This summary is machine-generated.

Researchers developed novel pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) as selective cannabinoid receptor 2 (CB2) ligands. Compounds 4g and 4h show high affinity for CB2, offering potential for treating neuroinflammation.

Keywords:
Cannabinoid receptors CB1/CB2central nervous system (CNS)neurodegenerative diseasesneuroinflammationpyrrolobenzodiazepines

More Related Videos

Solid Phase 11C-Methylation, Purification and Formulation for the Production of PET Tracers
09:25

Solid Phase 11C-Methylation, Purification and Formulation for the Production of PET Tracers

Published on: October 24, 2019

6.9K
Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.7K

Related Experiment Videos

Last Updated: Nov 11, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.8K
Solid Phase 11C-Methylation, Purification and Formulation for the Production of PET Tracers
09:25

Solid Phase 11C-Methylation, Purification and Formulation for the Production of PET Tracers

Published on: October 24, 2019

6.9K
Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.7K

Area of Science:

  • Medicinal Chemistry
  • Neuroscience
  • Pharmacology

Background:

  • Cannabinoid receptor 2 (CB2) is crucial in modulating microglial-derived neuroinflammation.
  • Selective CB2 ligands are sought for therapeutic intervention in neuroinflammatory conditions.
  • Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) represent a novel structural class with potential for targeting cannabinoid receptors.

Purpose of the Study:

  • To design and synthesize novel PBD analogs as potential selective ligands for CB2 receptors.
  • To evaluate the binding affinities and selectivity of the designed PBD analogs towards CB1 and CB2 receptors.
  • To explore the therapeutic potential of these compounds in the context of neuroinflammation.

Main Methods:

  • Computer-based docking studies utilizing the CB2 crystal structure.
  • Synthesis of a series of (S,E)-11-[2-(arylmethylene)hydrazono]-PBD analogs.
  • In vitro cannabinoid binding assays to determine binding affinities (Ki) for CB1 and CB2 receptors.
  • Assessment of compound stability at physiological pH.

Main Results:

  • Computational and theoretical studies indicated potential selectivity for CB1 and CB2.
  • Compounds 4g and 4h demonstrated selective binding to CB2 receptors with Ki values of 0.49 μM and 4.7 μM, respectively.
  • No significant binding to CB1 receptors was observed for compounds 4g and 4h.
  • The PBD analogs exhibited remarkable stability at physiological pH.

Conclusions:

  • The study reports the discovery of the first PBD analogs with selective binding to CB2 receptors.
  • The PBD tricyclic structure provides a suitable conformation for selective CB2 receptor interaction.
  • Attachment of heterocyclic rings enhances CB2 selectivity over CB1, suggesting therapeutic value for neuroinflammatory diseases.